Celltrion, Inc.
068270
Rang in Aktien
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aktienkurs
$146.63
Marktkapitalisierung
$33.44B
Veränderung (1 Tag)
-1.52%
Veränderung (1 Jahr)
23.60%
Land
KR
Handel Celltrion, Inc. (068270)
Kategorie
Healthcare
P/S-Verhältnis für Celltrion, Inc. (068270)
P/S-Verhältnis zum October 2026 TTM: 9.05
Laut den neuesten Finanzberichten und dem Aktienkurs von Celltrion, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 9.05. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 11.00.
P/S-Verlauf für Celltrion, Inc. von 2007 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 9.05 | -5.35% |
| 2025 | 9.56 | -13.03% |
| 2024 | 11.00 | -20.89% |
| 2023 | 13.90 | 56.92% |
| 2022 | 8.86 | -33.58% |
| 2021 | 13.34 | -44.98% |
| 2020 | 24.24 | 23.64% |
| 2019 | 19.61 | -22.93% |
| 2018 | 25.44 | -6.30% |
| 2017 | 27.15 | 50.86% |
| 2016 | 18.00 | 18.58% |
| 2015 | 15.18 | 74.48% |
| 2014 | 8.70 | -51.36% |
| 2013 | 17.88 | 122.72% |
| 2012 | 8.03 | -42.43% |
| 2011 | 13.95 | -26.33% |
| 2010 | 18.93 | 94.64% |
| 2009 | 9.73 | -8.79% |
| 2008 | 10.67 | 3,915.51% |
| 2007 | 0.27 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.72 | 18.49% |
US
|
|
| 41.70 | 360.86% |
US
|
|
| 4.19 | -53.68% |
AU
|
|
| 5.80 | -35.95% |
BE
|
|
| 10.44 | 15.41% |
NL
|
